Refine
Year of publication
Document Type
- Article (59)
- Doctoral Thesis (1)
Language
- English (60)
Has Fulltext
- yes (60)
Is part of the Bibliography
- no (60)
Keywords
- macrophage (8)
- inflammation (7)
- cancer (6)
- sphingosine-1-phosphate (6)
- tumor microenvironment (6)
- macrophage polarization (4)
- psoriasis (4)
- apoptosis (3)
- lung cancer (3)
- Breast cancer (2)
- Breast tumors (2)
- Immunology (2)
- Macrophages (2)
- NADPH oxidase (2)
- Nox1 (2)
- NoxO1 (2)
- Reactive oxygen species (2)
- angiogenesis (2)
- cancer-associated fibroblasts (2)
- colon (2)
- immunotherapy (2)
- lipocalin-2 (2)
- macrophages (2)
- mammary carcinoma (2)
- proliferation (2)
- reactive oxygen species (2)
- 3T3-L1 mouse fibroblasts (1)
- AGMO (1)
- Acute inflammation (1)
- Apoptosis (1)
- CD47 (1)
- COVID-19 (1)
- Cancer (1)
- Carcinogenese (1)
- Carotid injury (1)
- Cell binding (1)
- Cell death and immune response (1)
- Cell staining (1)
- Cytoskeleton (1)
- DNA methylation (1)
- Dermatitis (1)
- Ena/VASP proteins (1)
- Extracellular vesicles (1)
- Flow cytometry (1)
- G2A (1)
- GEMs (1)
- GPCR (1)
- Gene expression (1)
- Glycolysis (1)
- HCC marker (1)
- HIF-2 (1)
- Hepatocellular carcinoma (1)
- Hepatotoxicity (1)
- Hypoxia (1)
- IAP (1)
- IFN-β (1)
- IKKε (1)
- IL-1β (1)
- IL-27 cytokine (1)
- IL-33 (1)
- Immune cells (1)
- Inflammation (1)
- Iron (1)
- Jurkat (1)
- Kupffer cells (1)
- LASS (1)
- LDHB (1)
- Makrophage (1)
- Messenger RNA (1)
- Mitochondrial ROS (1)
- Mouse models (1)
- Mφs (1)
- NF-кB (1)
- NLRP3 inflammasomes (1)
- Nox4 (1)
- Oxidative phosphorylation (1)
- PD-L1 (1)
- Peritoneal macrophages (1)
- Physiology (1)
- Polyunsaturated fatty acid mediators (1)
- Psoriasis (1)
- RNA extraction (1)
- RNA isolation (1)
- RNA sequencing (1)
- RNA therapeutics (1)
- Restenosis (1)
- S1PR1 (1)
- S1PR4 (1)
- SARS-CoV-2 (1)
- SIRPalpha (1)
- SMAD (1)
- STAT1 (1)
- Single-cell RNA sequencing (1)
- Soluble epoxide hydrolase (1)
- Sphingolipidstoffwechsel (1)
- Superoxide (1)
- T-cell (1)
- TBK1 (1)
- TGFβ (1)
- VEGF receptor 2 internalization and signaling (1)
- Zymosan-induced peritonitis (1)
- acute inflammation (1)
- adenocarcinoma (1)
- adipocytes (1)
- alcoholic hepatitis (1)
- amlexanox (1)
- antiviral therapy (1)
- apoptotic cells (1)
- arachidonate 12/15-lipoxygenase (Alox12/15) (1)
- atherosclerosis (1)
- breast cancer (1)
- breast tumor (1)
- cancer metastases (1)
- ceramide synthase (1)
- chemokines (1)
- chemotherapy (1)
- compound screen (1)
- coronavirus (1)
- costimulation (1)
- cytokine (1)
- cytokine, angiogenesis (1)
- cytotoxic T cells (1)
- cytotoxic T lymphocyte (1)
- cytotoxic lymphocytes (1)
- cytotoxicity (1)
- diabetic nephropathy (1)
- diffusion-weighted magnetic resonance imaging (1)
- drug discovery (1)
- efferocytosis (1)
- endothelial cell (1)
- endothelial cells (1)
- enzyme activity assay (1)
- extracellular matrix (1)
- fatty acid (1)
- ferroportin (1)
- flow cytometry (1)
- gene expression (1)
- gene signature (1)
- hierarchical clustering (1)
- hypoxia (1)
- imiquimod (1)
- immune checkpoint (1)
- immunity (1)
- infection (1)
- interferon regulatory factor 9 (IRF9) (1)
- inflammation (1)
- iron (1)
- iron-trafficking (1)
- lipids (1)
- lipoxin A4 (1)
- liver (1)
- liver X receptor (1)
- lung tumor heterogeneity (1)
- lymphangiogenesis (1)
- mTORC (1)
- mammary cancer (1)
- mast cells (1)
- matrix metalloproteinase (1)
- melanoma (1)
- metabolism (1)
- metastasis (1)
- miR (1)
- microenvironment (1)
- migration (1)
- multiplexed immunofluorescence (1)
- multispectral flow cytometry (1)
- natural killer T cells (1)
- neoadjuvant chemoradiotherapy (1)
- nuclear factor 2 (erythroid-derived 2-like factor) (NFE2L2) (Nrf2) (1)
- oral cavity cancer (1)
- oxidative stress (1)
- p47phox (1)
- pain (1)
- peritoneal macrophages (1)
- peroxisome proliferator-activated receptor (1)
- phagocytosis (1)
- polarization (1)
- polyunsaturated fatty acid (1)
- predictive biomarker (1)
- prostaglandins (1)
- protein-protein interaction (1)
- rapamycin (1)
- renal cell carcinoma (1)
- resolution (1)
- resolution of inflammation (1)
- sepsis (1)
- signal transduction (1)
- specialized pro-resolving lipid mediators (SPMs) (1)
- sphingolipids (1)
- sprouting angiogenesis (1)
- tetrahydrobiopterin (1)
- tip cell filopodia formation (1)
- toll-like receptor (1)
- transcriptional profiling (1)
- transcriptome (1)
- tumor (1)
- tumor development (1)
- tumor growth (1)
- tumor immunity (1)
- tumor microenvironment (TME) (1)
- tumor progression (1)
- tumor stroma (1)
- tumor-associated macrophages (1)
- tumor-associated macrophages (TAM) (1)
- type I interferons (IFNs) (1)
- versican (VCAN) (1)
Institute
The lipid content of skin plays a determinant role in its barrier function with a particularly important role attributed to linoleic acid and its derivatives. Here we explored the consequences of interfering with the soluble epoxide hydrolase (sEH) on skin homeostasis. sEH; which converts fatty acid epoxides generated by cytochrome P450 enzymes to their corresponding diols, was largely restricted to the epidermis which was enriched in sEH-generated diols. Global deletion of the sEH increased levels of epoxides, including the linoleic acid-derived epoxide; 12,13-epoxyoctadecenoic acid (12,13-EpOME), and increased basal keratinocyte proliferation. sEH deletion (sEH-/- mice) resulted in thicker differentiated spinous and corneocyte layers compared to wild-type mice, a hyperkeratosis phenotype that was reproduced in wild-type mice treated with a sEH inhibitor. sEH deletion made the skin sensitive to inflammation and sEH-/- mice developed thicker imiquimod-induced psoriasis plaques than the control group and were more prone to inflammation triggered by mechanical stress with pronounced infiltration and activation of neutrophils as well as vascular leak and increased 12,13-EpOME and leukotriene (LT) B4 levels. Topical treatment of LTB4 antagonist after stripping successfully inhibited inflammation and neutrophil infiltration both in wild type and sEH-/- skin. While 12,13-EpoME had no effect on the trans-endothelial migration of neutrophils, like LTB4, it effectively induced neutrophil adhesion and activation. These observations indicate that while the increased accumulation of neutrophils in sEH-deficient skin could be attributed to the increase in LTB4 levels, both 12,13-EpOME and LTB4 contribute to neutrophil activation. Our observations identify a protective role of the sEH in the skin and should be taken into account when designing future clinical trials with sEH inhibitors.
Highlights
• TAM polarization induces CP RNA.
• CP RNA expression is regulated by HIF-2 and STAT1.
• CP RNA is transferred from TAMs to HT1080 cells.
• CP RNA is translated by HT1080 cells and protects from ferroptosis.
• Co-cultured HT1080 cells decrease iron and lipid peroxidation.
Abstract
Solid tumors are characterized by hypoxic areas, which are prone for macrophage infiltration. Once infiltrated, macrophages polarize to tumor associated macrophages (TAM) to support tumor progression. Therefore, the crosstalk between TAMs and tumor cells is of current interest for the development of novel therapeutic strategies. These may comprise induction of an iron- and lipid peroxidation-dependent form of cell death, known as ferroptosis. To study the macrophage - tumor cell crosstalk we polarized primary human macrophages towards a TAM-like phenotype, co-cultured them with HT1080 fibrosarcoma cells, and analyzed the tumor cell response to ferroptosis induction. In TAMs the expression of ceruloplasmin mRNA increased, which was driven by hypoxia inducible factor 2 and signal transducer and activator of transcription 1. Subsequently, ceruloplasmin mRNA was transferred from TAMs to HT1080 cells via extracellular vesicles. In tumor cells, mRNA was translated into protein to protect HT1080 cells from RSL3-induced ferroptosis. Mechanistically this was based on reduced iron abundance and lipid peroxidation. Interestingly, in naïve macrophages also hypoxia induced ceruloplasmin under hypoxia and a co-culture of HT1080 cells with hypoxic macrophages recapitulated the protective effect observed in TAM co-cultures. In conclusion, TAMs provoke tumor cells to release iron and thereby protect them from lipid peroxidation/ferroptosis.
Activation of the tumor-associated stroma to support tumor growth is a common feature observed in different cancer entities. This principle is exemplified by cancer-associated fibroblasts (CAFs), which are educated by the tumor to shape its development across all stages. CAFs can alter the extracellular matrix (ECM) and secrete a variety of different molecules. In that manner they have the capability to affect activation, survival, proliferation, and migration of other stromal cells and cancer cell themselves. Alteration of the ECM, desmoplasia, is a common feature of breast cancer, indicating a prominent role for CAFs in shaping tumor development in the mammary gland. In this review, we summarize the multiple roles CAFs play in mammary carcinoma. We discuss experimental and clinical strategies to interfere with CAFs function in breast cancer. Moreover, we highlight the issues arising from CAFs heterogeneity and the need for further research to identify CAFs subpopulation(s) that can be targeted to improve breast cancer therapy.
Hypoxia potentiates palmitate-induced pro-inflammatory activation of primary human macrophages
(2015)
Pro-inflammatory cytokines secreted by adipose tissue macrophages (ATMs) contribute to chronic low-grade inflammation and obesity-induced insulin resistance. Recent studies have shown that adipose tissue hypoxia promotes an inflammatory phenotype in ATMs. However, our understanding of how hypoxia modulates the response of ATMs to free fatty acids within obese adipose tissue is limited. We examined the effects of hypoxia (1% O2) on the pro-inflammatory responses of human monocyte-derived macrophages to the saturated fatty acid palmitate. Compared with normoxia, hypoxia significantly increased palmitate-induced mRNA expression and protein secretion of IL-6 and IL-1β. Although palmitate-induced endoplasmic reticulum stress and nuclear factor κB pathway activation were not enhanced by hypoxia, hypoxia increased the activation of JNK and p38 mitogen-activated protein kinase signaling in palmitate-treated cells. Inhibition of JNK blocked the hypoxic induction of pro-inflammatory cytokine expression, whereas knockdown of hypoxia-induced transcription factors HIF-1α and HIF-2α alone or in combination failed to reduce IL-6 and only modestly reduced IL-1β gene expression in palmitate-treated hypoxic macrophages. Enhanced pro-inflammatory cytokine production and JNK activity under hypoxia were prevented by inhibiting reactive oxygen species generation. In addition, silencing of dual-specificity phosphatase 16 increased normoxic levels of IL-6 and IL-1β and reduced the hypoxic potentiation in palmitate-treated macrophages. The secretome of hypoxic palmitate-treated macrophages promoted IL-6 and macrophage chemoattractant protein 1 expression in primary human adipocytes, which was sensitive to macrophage JNK inhibition. Our results reveal that the coexistence of hypoxia along with free fatty acids exacerbates macrophage-mediated inflammation.
The activation of the transcription factor NF-E2-related factor 2 (Nrf2) maintains cellular homeostasis in response to oxidative stress by the regulation of multiple cytoprotective genes. Without stressors, the activity of Nrf2 is inhibited by its interaction with the Keap1 (kelch-like ECH-associated protein 1). Here, we describe (3S)-1-[4-[(2,3,5,6-tetramethylphenyl) sulfonylamino]-1-naphthyl]pyrrolidine-3-carboxylic acid (RA839), a small molecule that binds noncovalently to the Nrf2-interacting kelch domain of Keap1 with a Kd of ∼6 μm, as demonstrated by x-ray co-crystallization and isothermal titration calorimetry. Whole genome DNA arrays showed that at 10 μm RA839 significantly regulated 105 probe sets in bone marrow-derived macrophages. Canonical pathway mapping of these probe sets revealed an activation of pathways linked with Nrf2 signaling. These pathways were also activated after the activation of Nrf2 by the silencing of Keap1 expression. RA839 regulated only two genes in Nrf2 knock-out macrophages. Similar to the activation of Nrf2 by either silencing of Keap1 expression or by the reactive compound 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester (CDDO-Me), RA839 prevented the induction of both inducible nitric-oxide synthase expression and nitric oxide release in response to lipopolysaccharides in macrophages. In mice, RA839 acutely induced Nrf2 target gene expression in liver. RA839 is a selective inhibitor of the Keap1/Nrf2 interaction and a useful tool compound to study the biology of Nrf2.
Macrophages constitute a major part of the tumor-infiltrating immune cells. Within the tumor microenvironment, they acquire an alternatively activated, tumor-supporting phenotype. Factors released by tumor cells are crucial for the recruitment of tumor-associated macrophages. In the present project, we aimed to understand the role of hsa-miR-200c-3p (miR-200c) in the interplay between tumor cells and macrophages. To this end, we employed a coculture system of MCF7 breast tumor cells and primary human macrophages and observed the transfer of miR-200c from apoptotic tumor cells to macrophages, which required intact CD36 receptor in macrophages. We further comprehensively determined miR-200c targets in macrophages by mRNA-sequencing and identified numerous migration-associated mRNAs to be downregulated by miR-200c. Consequently, miR-200c attenuated macrophage infiltration into 3-dimensional tumor spheroids. miR-200c-mediated reduction in infiltration further correlated with a miR-200c migration signature comprised of the four miR-200c-repressed, predicted targets PPM1F, RAB11FIB2, RDX, and MSN.
The sphingolipid sphingosine-1-phosphate (S1P) promotes tumor development through a variety of mechanisms including promoting proliferation, survival, and migration of cancer cells. Moreover, S1P emerged as an important regulator of tumor microenvironmental cell function by modulating, among other mechanisms, tumor angiogenesis. Therefore, S1P was proposed as a target for anti-tumor therapy. The clinical success of current cancer immunotherapy suggests that future anti-tumor therapy needs to consider its impact on the tumor-associated immune system. Hereby, S1P may have divergent effects. On the one hand, S1P gradients control leukocyte trafficking throughout the body, which is clinically exploited to suppress auto-immune reactions. On the other hand, S1P promotes pro-tumor activation of a diverse range of immune cells. In this review, we summarize the current literature describing the role of S1P in tumor-associated immunity, and we discuss strategies for how to target S1P for anti-tumor therapy without causing immune paralysis.
To better understand the role of sphingolipids in the multifactorial process of inflammatory bowel disease (IBD), we elucidated the role of CerS4 in colitis and colitis-associated cancer (CAC). For this, we utilized the azoxymethane/dextran sodium sulphate (AOM/DSS)-induced colitis model in global CerS4 knockout (CerS4 KO), intestinal epithelial (CerS4 Vil/Cre), or T-cell restricted knockout (CerS4 LCK/Cre) mice. CerS4 KO mice were highly sensitive to the toxic effect of AOM/DSS, leading to a high mortality rate. CerS4 Vil/Cre mice had smaller tumors than WT mice. In contrast, CerS4 LCK/Cre mice frequently suffered from pancolitis and developed more colon tumors. In vitro, CerS4-depleted CD8+ T-cells isolated from the thymi of CerS4 LCK/Cre mice showed impaired proliferation and prolonged cytokine production after stimulation in comparison with T-cells from WT mice. Depletion of CerS4 in human Jurkat T-cells led to a constitutively activated T-cell receptor and NF-κB signaling pathway. In conclusion, the deficiency of CerS4 in T-cells led to an enduring active status of these cells and prevents the resolution of inflammation, leading to a higher tumor burden in the CAC mouse model. In contrast, CerS4 deficiency in epithelial cells resulted in smaller colon tumors and seemed to be beneficial. The higher tumor incidence in CerS4 LCK/Cre mice and the toxic effect of AOM/DSS in CerS4 KO mice exhibited the importance of CerS4 in other tissues and revealed the complexity of general targeting CerS4.
Background: Glucose metabolism in the tumor-microenvironment is a fundamental hallmark for tumor growth and intervention therein remains an attractive option for anti-tumor therapy. Whether tumor-derived factors such as microRNAs (miRs) regulate glucose metabolism in stromal cells, especially in tumor-associated macrophages (TAMs), to hijack them for trophic support, remains elusive.
Methods: Ago-RIP-Seq identified macrophage lactate dehydrogenase B (LDHB) as a target of tumor-derived miR-375 in both 2D/3D cocultures and in murine TAMs from a xenograft mouse model. The prognostic value was analyzed by ISH and multiplex IHC of breast cancer patient tissues. Functional consequences of the miR-375-LDHB axis in TAMs were investigated upon mimic/antagomir treatment by live metabolic flux assays, GC/MS, qPCR, Western blot, lentiviral knockdown and FACS. The therapeutic potential of a combinatorial miR-375-decoy/simvastatin treatment was validated by live cell imaging.
Results: Macrophage LDHB decreased in murine and human breast carcinoma. LDHB downregulation increase aerobic glycolysis and lactagenesis in TAMs in response to tumor-derived miR-375. Lactagenesis reduced fatty acid synthesis but activated SREBP2, which enhanced cholesterol biosynthesis in macrophages. LDHB downregulation skewed TAMs to function as a lactate and sterol/oxysterol source for the proliferation of tumor cells. Restoring of LDHB expression potentiated inhibitory effects of simvastatin on tumor cell proliferation.
Conclusion: Our findings identified a crucial role of LDHB in macrophages and established tumor-derived miR-375 as a novel regulator of macrophage metabolism in breast cancer, which might pave the way for strategies of combinatorial cancer cell/stroma cell interventions.
The nuclear factor kappa beta (NFκB) signaling pathway plays an important role in liver homeostasis and cancer development. Tax1-binding protein 1 (Tax1BP1) is a regulator of the NFκB signaling pathway, but its role in the liver and hepatocellular carcinoma (HCC) is presently unknown. Here we investigated the role of Tax1BP1 in liver cells and murine models of HCC and liver fibrosis. We applied the diethylnitrosamine (DEN) model of experimental hepatocarcinogenesis in Tax1BP1+/+ and Tax1BP1−/− mice. The amount and subsets of non-parenchymal liver cells in in Tax1BP1+/+ and Tax1BP1−/− mice were determined and activation of NFκB and stress induced signaling pathways were assessed. Differential expression of mRNA and miRNA was determined. Tax1BP1−/− mice showed increased numbers of inflammatory cells in the liver. Furthermore, a sustained activation of the NFκB signaling pathway was found in hepatocytes as well as increased transcription of proinflammatory cytokines in isolated Kupffer cells from Tax1BP1−/− mice. Several differentially expressed mRNAs and miRNAs in livers of Tax1BP1−/− mice were found, which are regulators of inflammation or are involved in cancer development or progression. Furthermore, Tax1BP1−/− mice developed more HCCs than their Tax1BP1+/+ littermates. We conclude that Tax1BP1 protects from liver cancer development by limiting proinflammatory signaling.